COLUMBIA UNIVERSITY INSTITUTIONAL REVIEW BOARD POLICY
NONCOMPLIANCE WITH HUMAN SUBJECT REGULATIONS

I. SCOPE:

This is a University-wide Policy for responding to allegations of noncompliance with laws, regulations, or institutional or governmental policies governing the protection of human subjects in research. This Policy applies to all individuals, including Officers of Instruction, Officers of Research, students and employees, who may be involved in human subjects research conducted under the auspices of either Columbia University (the “University”), including Columbia University Medical Center (“CUMC”), or NewYork Presbyterian Hospital (“NYP”) and all human subjects research conducted by such individuals.

This Policy does not relate to research misconduct involving fabrication, falsification or plagiarism of research or research results which is covered by the Columbia University Institutional Policy on Misconduct in Research.

II. EFFECTIVE DATE: January 23, 2006; Revised December 1, 2009; Revised February 26, 2010

III. BACKGROUND:

The University is responsible for protecting the safety and welfare of human subjects participating in research conducted under the auspices of the University. In addition, NYP has designated the CUMC IRB for the review of human subjects research and the University and NYP share the responsibility for protecting the safety and welfare of human subjects participating in research at NYP. These responsibilities include establishing a policy for responding to allegations of noncompliance with laws, regulations or institutional or governmental policies concerning human subjects research and taking appropriate action(s) with respect to such allegations. This Policy is designed to address these issues.

Definitions of certain key terms used in this Policy are provided in Section VIII.

For purposes of this Policy, “Noncompliance” means a failure to comply with University policy (including requirements imposed by the IRB during review of a research study) or applicable federal and state laws, regulations and policies governing the protection of human subjects in research.

This Policy covers two types of Noncompliance: Research Noncompliance and IRB Noncompliance. “Research Noncompliance” means Noncompliance by anyone other than a member of the IRB (IRB staff or member in his/her capacity as such). “IRB
**Noncompliance** means Noncompliance by any member of the IRB (IRB staff or member in his/her capacity as such).

A response to an allegation of Noncompliance consists of three phases:

1. **Inquiry:** the gathering of preliminary information and fact-finding to assess whether an allegation has substance and, if so, whether an Investigation is warranted (an “Inquiry”);

2. **Investigation:** following an Inquiry, the further investigation of facts with respect to whether Noncompliance has occurred (an “Investigation”); and

3. **Outcome:** following an Investigation, the determination as to whether Noncompliance has occurred and what corrective action(s), if any, are required (an “Outcome”).

**IV. RESEARCH NONCOMPLIANCE:**

**A. THE MAKING OF AN ALLEGATION**

1. Concerns about possible Research Noncompliance may be discussed with an IRB Chair, the Executive Director, the Associate Director, an IRB Manager, or staff member of the IRB Compliance Oversight Team (COT). If the concerns involve serious and/or continuing or recurrent Noncompliance or Noncompliance that affects studies reviewed by more than one IRB, such concerns may also be discussed with the Executive Vice President for Research (EVPR).

Serious Noncompliance is defined as a failure to follow the regulations and policies of the IRB or the IRB-approved protocol and in the judgment of the COT or the designated IRB increases risks to subjects, compromises the rights and welfare of the subjects, and/or compromises the integrity of the research study. Serious Research Noncompliance may include, but is not limited to: (a) the failure to obtain or maintain IRB approval before conducting any Human Subjects Research; (b) the enrollment of subjects in a study without obtaining legally effective informed consent; or (c) the failure to report serious or recurring problems involving risks to Human Subjects.

Continuing Noncompliance is any Noncompliance that consistently or intermittently continued after the Noncompliance was confirmed by the designated IRB or the COT or any regulatory or sponsoring entity and the Principal Investigator was notified of such Noncompliance.

2. All incidents of possible Research Noncompliance should be documented in writing and reported promptly (ideally within five business days of discovery) to the COT Manager and copied to the Executive Director and Associate Director of the IRB in
accordance with the terms of this Policy. Any individual may make an allegation of Noncompliance.

3. Any allegation of serious Research Noncompliance that may affect the protection of human subjects must also be promptly reported by the COT or the Executive Director to the Relevant IRB Chair, the IRB Executive Committee (IEC), and at the discretion of the Executive Director, the appropriate Responsible Academic Officer.

B. THE INQUIRY PHASE

1. The Inquiry with respect to any alleged Research Noncompliance shall be conducted by the COT, with the exception of inquiries of certain non-serious, or minor, noncompliance that is identified by the designated IRB as outlined in Appendix 1.

2. The Inquiry shall be completed promptly and, at its conclusion, the COT Manager shall report to the Executive Director the COT’s findings as to whether or not there is sufficient evidence to undertake an Investigation (i.e., alleged noncompliance was possible given the reported information; for example, the investigator is conducting the study and the alleged infraction was possible for the given study).

3. The Executive Director will authorize an Investigation if there is sufficient evidence after the Inquiry Phase that the allegation is plausible, and he/she or the COT Manager shall so notify the Respondent of such a decision. The Executive Director may, in his/her discretion, also notify one or more of the other Need to Know Individuals (see Definitions in section VIII). If the Executive Director does not agree with the findings of the inquiry he/she may decide that an investigation will not be conducted and shall promptly report his/her decision to the Relevant Chair or the IEC, if the study has not been assigned to an IRB.

C. THE INVESTIGATION PHASE

1. If the Executive Director decides that an Investigation is warranted, he/she shall direct the COT to proceed with such Investigation. As noted in B.1 above the investigation of certain non-serious, or minor, noncompliance that is identified by the designated IRB may be investigated by that IRB as outlined in Appendix 1.

2. The COT shall complete the Investigation promptly and, at its conclusion, shall submit a written report (the “Preliminary Investigation Report”) to (a) the Executive Director, or IEC, as applicable; and (b) the Relevant IRB Chair and IRB Manager. The Preliminary Investigation Report shall include the COT’s determination as to whether a finding of Noncompliance should be made and, if so, the COT’s recommendation as to which corrective action(s) should be taken.

3. The Executive Director, or in the case of serious Research Noncompliance, the IRB or IEC, may accept, reject or modify the conclusions of the COT in the Preliminary Investigation Report.
D. THE OUTCOME PHASE

This section describes the process for the Outcome Phase for cases managed by the COT. For minor Research Noncompliance that was managed by the IRB in accordance with Appendix 1, the alleged noncompliance will be reported to the COT for tracking purposes.

1. If a finding of Research Noncompliance has been made, the finding(s) will be reported to the designated IRB for review and an initial determination of any necessary corrective action(s). For consistency of corrective action plans and outcomes of noncompliance cases (especially for noncompliance cases that involve studies reviewed by more than one IRB), the Executive Director or, in the case of serious Research Noncompliance, the IEC shall make final decisions regarding which corrective action(s) should be taken.

If a finding of serious Research Noncompliance is made involving any IRB member who is involved in the conduct of the research, the finding will be reviewed solely by the IEC and not the designated IRB (in order to eliminate any conflicts of interest that may exist on behalf of the designated IRB).

Any final determinations or decisions regarding Research Noncompliance made by the Executive Director, or determinations regarding serious Research Noncompliance made by the IEC if inconsistent with the IRB’s initial determination will be reported back to the designated IRB. Any concerns raised by the designated IRB regarding the final determinations made by the Executive Director or the IEC should be reported to the IEC for reconsideration.

2. Corrective action(s) may include any of the following:

   a. suspension or termination of the Principal Investigator’s research protocol(s);

   b. required training with respect to Human Subjects Research and the regulatory requirements for the conduct of such Research;

   c. imposition of changes in such research protocol(s) to further protect Human Subjects;

   d. imposition of restrictions as a condition for the continuation of research by the Principal Investigator;

   e. destruction of data collected during the period of Noncompliance;

   f. disallowance of the publication of data collected during the period of Noncompliance;

   g. oversight monitoring by the COT; and
h. any other appropriate action.

3. Following the decision of the Executive Director or the IEC, as the case may be, as to the appropriate corrective action(s), a written report (the “Investigation Report”) shall be prepared, incorporating the COT’s findings and the decisions of the Executive Director or the IEC with respect to the finding of Research Noncompliance and the corrective action(s), if any.

4. The Executive Director shall promptly notify the Respondent of his/her or the IEC’s decision and shall provide the Respondent with an opportunity to respond to the Investigation Report within a specified time period. At the end of such period, the Executive Director or, in the case of serious Research Noncompliance, the IEC, shall promptly review the Respondent’s response and shall make a final decision as to the finding of Research Noncompliance and the corrective action(s) required, if any. The Executive Director shall notify the Need to Know Individuals of his/her or the IEC’s decision.

E. APPEAL

1. A Respondent shall have the right, within 30 days after his/her receipt of notification of the decision of the Executive Director or the IEC at the end of the Outcome Phase, to file a written appeal with the EVPR as to either the finding of Noncompliance or the corrective action(s) required. If the Principal Investigator is at CUMC, the EVPR shall send a copy of the appeal to the Senior Vice Dean, College of Physicians and Surgeons (SVD) and shall consult with the SVD as to the merits of the appeal. The EVPR may affirm, reject or modify the decision of the Executive Director or the IEC. The decision of the EVPR shall be final in all respects and the Respondent shall have no further right of appeal.

2. Notice of the decision of the EVPR with respect to any appeal shall be given to the Need to Know Individuals.

V. IRB NONCOMPLIANCE:

A. THE MAKING OF AN ALLEGATION

1. Concerns about possible IRB Noncompliance may be discussed with an IRB Chair, the Executive Director or the Associate Director. If the concerns involve Noncompliance by the Executive Director or the failure by any member of an IRB or the IRB staff to correct serious and/or continuing or recurrent incidents of Noncompliance (“Serious IRB Noncompliance”), such concerns may also be discussed with the EVPR.

2. All incidents of possible IRB Noncompliance shall be reported to the IRB or the EVPR in accordance with the terms of this Policy. Any individual may make an
allegation of IRB Noncompliance. An allegation of IRB Noncompliance shall be made in writing and given to the Executive Director or the Associate Director or, in the case of Serious IRB Noncompliance, to the EVPR.

3. Prompt notice of any allegation of Serious IRB Noncompliance shall be given by the EVPR to the IEC and, in the case of Serious Noncompliance at CUMC, to the CUMC Institutional Official.

B. THE INQUIRY PHASE

1. The Inquiry with respect to any alleged IRB Noncompliance (other than Serious IRB Noncompliance) shall be conducted by the COT or, at his/her discretion, the Executive Director. In the case of Serious IRB Noncompliance, the Inquiry shall be conducted by the EVPR or such qualified persons as the EVPR shall select (the “Inquirers”).

2. The Inquiry shall be completed promptly and, at its conclusion, the Executive Director shall decide or, if the Inquiry has been conducted by the COT, the COT Manager shall report to the Executive Director its findings as to, whether or not there is sufficient evidence to undertake an Investigation. In the case of Serious IRB Noncompliance, the Inquirers shall report to the EVPR their findings as to whether or not there is sufficient evidence to undertake an Investigation.

3. If the Inquiry has been conducted by the COT, the Executive Director may accept or reject its findings. In the case of Serious IRB Noncompliance, the EVPR may accept or reject the findings of the Inquirers. In either case, the Executive Director or EVPR shall promptly report the decision to the IEC. If the Executive Director or the EVPR decides that an Investigation is warranted, he/she shall so notify the Respondent. The Executive Director or the EVPR, as the case may be, may, in his/her discretion, also notify one or more of the other Need to Know Individuals.

C. THE INVESTIGATION PHASE

1. If the Executive Director decides that an Investigation is warranted, it shall be conducted by the COT or, at his/her discretion, by the Executive Director. In the case of Serious IRB Noncompliance, the Investigation shall be conducted by the EVPR or such qualified persons as the EVPR shall select (the “Reviewers”).

2. The Investigation shall be completed promptly and, at its conclusion, if the Investigation has been conducted by the COT, the COT Manager shall submit a written report (the “Preliminary IRB Investigation Report”) to the Executive Director. If the Executive Director has conducted the Investigation, he/she shall prepare the Preliminary IRB Investigation Report. In the case of Serious IRB Noncompliance, the Preliminary IRB Investigation Report shall be submitted by the Reviewers to the EVPR. The Preliminary IRB Investigation Report shall include a determination as to whether a finding of Noncompliance should be made and, if so, a recommendation of the Executive
Director or the Reviewers, as the case may be, as to what corrective action(s) should be taken.

3. If the Investigation has been conducted by the COT, the Executive Director may accept, reject or modify the conclusions in the Preliminary IRB Investigation Report. In the case of Serious IRB Noncompliance, the EVPR may accept, reject or modify such conclusions.

D. THE OUTCOME PHASE

1. If a finding of IRB Noncompliance has been made, the Executive Director or, in the case of Serious IRB Noncompliance, the EVPR shall decide which corrective action(s) should be taken.

2. Corrective action(s) may include any of the following:

   a. required training with respect to Human Subjects Research and the regulatory requirements relating to such Research;

   b. if the Respondent is a member of the IRB staff, suspension or termination of employment;

   c. if the Respondent is a member of an IRB, suspension or termination of appointment to the IRB; and

   d. any other appropriate action.

3. Following the decision of the Executive Director or the EVPR, as the case may be, as to the appropriate corrective action(s), a written report (the “IRB Investigation Report”) shall be prepared, incorporating the decisions of the Executive Director or the EVPR with respect to the finding of IRB Noncompliance and the corrective action(s), if any.

4. The Executive Director or, in the case of Serious IRB Noncompliance, the EVPR shall promptly notify the Respondent of his/her decision and shall provide the Respondent with an opportunity to respond to the Investigation Report within a specified time period. At the end of such period, the Executive Director or, in the case of Serious Noncompliance, the EVPR shall promptly review the Respondent’s response and shall make a final decision as to the finding of IRB Noncompliance and the corrective action(s) required, if any. The Executive Director or, in the case of Serious IRB Noncompliance, the EVPR shall notify the Need to Know Individuals of his/her decision.

E. RECONSIDERATION

1. A Respondent with respect to whom a finding of IRB Noncompliance has been made shall have the right, within 30 days after his/her receipt of the notification of the
Executive Director’s or the EVPR’s decision at the end of the Outcome Phase, to request a reconsideration of the decision by the EVPR as to either the finding of Noncompliance or the corrective action(s) imposed. The EVPR may or may not reconsider the decision. The decision of the EVPR shall be final in all respects and the Respondent shall have no further right of reconsideration or appeal.

2. Notice of the decision of the EVPR with respect to any request for reconsideration shall be given to the Need to Know Individuals.

VI. SAFEGUARDS:

A. Confidentiality: To the extent possible consistent with a fair and thorough investigation and as allowed by law, knowledge about the identity of a Complainant, a Respondent and any witnesses shall be limited to those persons identified in this Policy and others who need to know and all written materials and information with respect to any proceedings shall be kept confidential.

B. Evidence: During each phase of the administrative proceedings described in this Policy, such evidence shall be reviewed and such persons shall be interviewed as shall be necessary to make a reasonable determination as whether an allegation of Noncompliance does or does not merit an Investigation, whether a finding of Noncompliance should be made or what corrective action(s) should be imposed.

C. Sequestration: During any Inquiry or Investigation, a determination should be made if any information, including any IRB files, should be sequestered and, if sequestered, the terms under which such information may be accessed.

D. Safeguards for a Complainant: If an allegation of Noncompliance has been made in good faith, the University shall ensure that a Complainant is treated fairly and reasonably, that diligent efforts are made to protect the position and reputation of the Complainant and that the Complainant is not subject to retaliation.

E. Safeguards for a Respondent:

1. To the extent consistent with the protection of Human Subjects, a Respondent is assumed not to have been Noncompliant until a finding of such has been made in accordance with this Policy. The Respondent in turn shall cooperate with the administrative procedures described in this Policy, including by providing information, records and evidence to the University representatives referred to herein when so requested.

2. The University shall not impede the ability of a Respondent to continue to involve Human Subjects in his/her research, to remain employed as an IRB staff member or to serve as an IRB Member, as applicable, during the period of any of the administrative procedures described in this Policy unless the Executive Director, the IEC or the EVPR
determines that there are compelling reasons to suspend the Respondent’s right to do so during all or a portion of such period.

3. During an Inquiry, the Respondent shall be provided the opportunity to meet with the persons responsible for the Inquiry and to respond to the allegation orally and in writing.

4. During an Investigation, the Respondent shall have the right to present testimony and documents on his/her behalf.

**F. Responsibilities of the COT Manager:** The COT Manager shall notify the EVPR directly if, in his/her judgment, any allegation and/or subsequent Inquiry, Investigation and/or Outcome failed to be conducted in good faith and/or to comply with University policy or applicable law or regulations.

**G. Conflicts of Interest:** Any individual who undertakes any action(s) outlined in this Policy shall do so without conflict or personal involvement in the alleged Noncompliance. If such a personal conflict is identified, that individual shall recuse him/herself from the administrative procedures described in this Policy.

**VII. NOTIFICATION TO REGULATORY AGENCIES OR FUNDING SOURCES:**

The Executive Director or in the case of Serious IRB Noncompliance, the EVPR, shall report allegations of serious Research Noncompliance to the appropriate regulatory agency and sponsors as required by applicable law or regulations.

All serious Research Noncompliance and Serious IRB Noncompliance will minimally be reported to OHRP, Director of Compliance Oversight. If the research involves an investigational drug, the case will also be reported to FDA, Division of Scientific Investigations, Office of Compliance. If the research involves an investigational device, the case will also be reported to the FDA/Center for Devices and Radiological Health (CDRH), Director, Division of Bioresearch Monitoring.

Allegations that fall outside of the mandatory reporting requirements shall be reported to the regulatory agency, the funding source, or any other relevant person(s) involved in the research project at the discretion of the Executive Director or the EVPR, as the case may be.

**VIII. DEFINITIONS:**

“**Associate Director**”: the Associate Director of the IRB.

“**Complainant**”: the person bringing an allegation of Noncompliance.
“Continuing noncompliance”: any Noncompliance that consistently or intermittently continued after the Noncompliance was confirmed by the designated IRB or the COT or any regulatory or sponsoring entity and the Principal Investigator was notified of such Noncompliance.

“COT”: the Compliance Oversight Team of the IRB.

“COT Manager”: the Manager of the COT.

“EVPR”: the Executive Vice President for Research of the University.

“Executive Director”: the Executive Director of the University’s Human Research Protection Program and the IRB.

“Human Subject”: (a) a living individual about whom an investigator (whether professional or student) conducting Research obtains (i) data through intervention or interaction with the individual or (ii) identifiable private information or (b) a living individual who is or becomes a participant in Research, either a recipient of a test article or is a control.


“Institutional Official”: (a) the Executive Vice President for Research (EVPR), (b) with respect to CUMC, the Senior Vice Dean, College of Physicians and Surgeons (SVD), and (c) with respect to NYP, the Group Senior Vice President, Chief Operating Officer and Chief Medical Officer.

“IRB”: any of the University’s Institutional Review Boards or all of the University’s Institutional Review Boards, collectively, as the context requires.

“IRB Executive Committee”: the Executive Committee of the IRB (IEC), consisting of the Executive Director, the Associate Director, the IRB Chairs, the IRB Vice Chairs and the Vice President for Research Operations.

“IRB Noncompliance”: Noncompliance by any member of the IRB (IRB staff or member in his/her capacity as such).

“Need to Know Individuals”: (a) with respect to any allegation of Research Noncompliance, (i) the Principal Investigator, (ii) the Respondent, (iii) the IRB Chairs and Vice Chairs, (iv) the appropriate Responsible Academic Officer, (v) the appropriate Institutional Official, (vi) the Director of the Clinical Trials Office and the Director of the IND/IDE Assistance Program in the case of Noncompliance with FDA-regulated research; and (vii) such other persons as the Executive Director or, in the case of serious Research Noncompliance, the IEC shall select; and
(b) with respect to any allegation of IRB Noncompliance, (i) the Respondent, (ii) the appropriate Institutional Official, (iii) in the case of Serious IRB Noncompliance, the IEC and (iv) such other persons as the Executive Director or, in the case of Serious IRB Noncompliance, the EVPR shall select.

“Noncompliance”: a failure to comply with University policy (including requirements imposed by the IRB during review of a research study) or applicable federal and state laws, regulations and policies governing the protection of human subjects in research.

“Principal Investigator”: with respect to any allegation of Noncompliance, the principal investigator of the research study to which such allegation relates.

“Relevant IRB Chair”: with respect to any allegation of Noncompliance, the Chair of the relevant IRB.

“Research”: a systematic investigation, including research development, testing and evaluation, designed to develop or contribute to general knowledge.

“Research Noncompliance”: Noncompliance by anyone other than a member of the IRB (IRB staff or member in his/her capacity as such).

“Respondent”: the person, including a Principal Investigator, who is the subject of an allegation of Noncompliance.

“Responsible Academic Officer”: with respect to any Principal Investigator, the Chair, Dean or Director of the Department, School, Institute or Center of which such Principal Investigator is a member.

“Serious Noncompliance”: a failure to follow the regulations and policies of the IRB and in the judgment of the COT or the designated IRB increases risks to subjects, compromises the rights and welfare of the subjects, and/or compromises the integrity of the research study.
Appendix 1

Policy for IRB Review of Minor Noncompliance

This Policy provides direction as to which incidents of potential noncompliance should be handled by the IRB rather than the Compliance Oversight Team (COT). All types of minor noncompliance that are listed in this policy and were discovered by an IRB upon review of a submission may be reviewed by the designated IRB rather than the COT.

If at any time, the Board/Manager/Chair determines that an investigator has Continuing and/or Serious Noncompliance, then the Manager should refer the case directly to the COT for an investigation. The IRB should proceed with the review and may choose to suspend research activities if it lacks adequate information regarding the impact of potential noncompliance on the protection of human subjects.

I. Types of Noncompliance that may be reviewed by the IRB:

Possible non-compliance including protocol violations not limited to the following should generally fall under the Board’s purview. These situations are usually considered to be not reportable to OHRP.

A. Over-enrollment of Subjects

For a minimal risk study, over-enrollment is generally considered to be minor noncompliance. The Board/Team Manager/Chair should notify the Principal Investigator (PI) that the over enrollment is noncompliance with Federal regulations and obtain a written acknowledgement from the investigator that in the future they will not enroll more subjects than was approved by the IRB. The Board will then:

- determine whether or not the over-enrollment is minor noncompliance;
- determine whether to allow use of the data from the subjects over the approved number;
- determine if a corrective action plan is required; if so, the Board/Manager/Chair should request it for immediate review. Corrective action plans should be requested in all situations in which a significant number of subjects were enrolled beyond the sample size previously approved by the IRB.

For over-enrollment in a greater than minimal risk study, or if a pattern of over-enrollment is observed in any study, it should be referred to the COT for consideration of whether an investigation of the study may be appropriate and if it constitutes Continuing or Serious noncompliance.
B. Performance of Research Activities During a Lapse in IRB Approval

1. Performance of data analysis during a lapse in IRB approval:

If data analysis occurred or there is a reason to suspect that data analysis may have occurred during a lapse, the Board/Manager/Chair should:

- determine if any data analysis occurred and establish the extent of study-related activity during the lapse. If study-related procedures (e.g., follow-up interaction with subjects), then proceed to item 2 below;
- determine whether or not the data analysis and study-related activity during a lapse in IRB approval is minor noncompliance;
- request a written statement from the investigator that human subjects research including analysis of data will not occur if a lapse of approval occurred again in the future.

2. Performance of study related procedures other than data analysis during lapse in IRB approval

   a) Minimal risk research

   If an investigator actively recruits or enrolls subjects or conducts study interventions or procedures during a lapse in approval or there is reason to suspect that study-related procedures may have been conducted during a lapse, the Manager/Chair/Board should:

   - determine the extent of noncompliance (e.g., the procedures conducted, the number of subjects that were involved in the research conducted during the lapse, the individuals who conducted the procedures during the lapse, any other relevant information);
   - determine whether or not the study-related procedures performed during a lapse were minor noncompliance;
   - determine whether to allow use of the data from the procedures performed during the lapse;
   - determine if a corrective action plan is required; if so, the Board/Manager/Chair should request it for immediate review. Corrective action plans should be requested in all situations in which subjects were enrolled or a significant amount of research activity occurred during a lapse in approval.

   b) Greater than minimal risk research

   If an investigator actively recruits or enrolls subjects or conducts study interventions or procedures during a lapse in approval or there is reason to suspect that study-related procedures may have been conducted during a lapse, the study should be referred to the COT for further investigation.
C. Exempt Research

If an investigator conducts study interventions or procedures (or there is reason to suspect that study-related procedures may have been conducted) in a manner whereby the research study would no longer qualify as exempt, the IRB should:

- determine the extent of noncompliance;
- determine whether or not the study-related procedures performed were minor noncompliance;
- determine whether to allow use of the data from the procedures performed during the lapse;
- determine if a corrective action plan is required; if so, the Board/Manager/Chair should request it for immediate review. Corrective action plans should be requested in all situations in which study-related procedures were performed that would be significantly beyond an exempt determination.

D. Protocol Violations

As defined in the IRB Policies and Procedures, section V.B.6., a protocol violation is defined as a protocol change or modification that was not approved by the IRB and is identified by the research staff after the change was implemented. Protocol violations may be considered as noncompliance with the federal regulations for the protection of human subjects.

Major and minor protocol violations are defined in sections VI.C.4.a. and VI.C.4.b., respectively, of the IRB Policies and Procedures. Minor protocol violations may be reviewed by the IRB to which the protocol is assigned; major protocol violations should generally be managed by the COT.

The IRB should determine whether or not the protocol violation(s) performed are serious or minor noncompliance. If it appears that the protocol violation(s) may be Serious Noncompliance, the violation(s) should be referred to the COT for further investigation.

If a protocol violation is determined to be minor, the Board/Manager/Chair should:

- determine the extent of potential noncompliance;
- determine whether to allow use of the data collected as a result of the violation(s);
- determine if a corrective action plan is required; if so, the Board/Manager/Chair should request it for immediate review. Corrective action plans should be requested in all situations in which there were a significant number of protocol violation(s) or the violations may have reflected inappropriate management of the study.
All protocol violations, regardless of compliance considerations, should be reviewed promptly by the designated IRB for consideration of how the protection of human subjects may be affected by the violations. For situations in which the IRB requires more information about the violations in order to make such determinations, the IRB may request an investigation from the COT.

E. Other incidents of noncompliance that may be considered minor noncompliance

Other incidents of minor noncompliance that are not listed above and that are discovered by a designated IRB upon review of a submission may be reviewed by the designated IRB after: a) consultation between the ED or AD and the IRB Chair or Manager; and b) agreement that the IRB will review and manage the situation.

Examples of such incidents include:
   i) the PI did not sign a consent document and the PI’s signature is specifically requested on the IRB-approved consent document;
   ii) a subject did not sign the appropriate IRB-stamped consent document but all of the content of the consent document is the same;
   iii) failure to have a HIPAA Form A signed by a subject.

II. Processing of potential minor noncompliance by the IRB
   • the designated IRB must document the above mentioned findings in RASCAL (e.g., notes, minutes, correspondence, internal documents, etc.);
   • For all compliance inquiries and investigations, a copy of all corrective actions received by the IRB should be attached in RASCAL;
   • All incidents of potential noncompliance that will be handled by the IRB in accordance with this policy must be reported to the COT for tracking purposes.